



## **Thomas Ackerman and Dan Bevevino Join Cryolife, Inc. Board of Directors**

December 8, 2003

ATLANTA, Dec. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Thomas F. Ackerman and Dan Bevevino have been elected to the company's Board of Directors, effective immediately. These two, newly elected board members increase the number of directors to eight.

Thomas F. Ackerman is Senior Vice President and Chief Financial Officer at Charles River Laboratories, a provider of critical research tools and integrated support services that accelerate drug discovery and research. He is responsible for overseeing the Accounting and Finance departments, as well as the Information Technology Group and Investor Relations. Mr. Ackerman joined Charles River Laboratories in 1988 and now has more than twenty-five years of combined accounting and international finance experience. He was named Controller, North America in 1992 and became Vice President and Chief Financial Officer in 1996. In 1999, he was named Senior Vice President.

Dan Bevevino is Vice President and Chief Financial Officer at Respiroics, a developer, manufacturer and marketer of medical devices and programs used for the treatment of patients with sleep and respiratory disorders. Mr. Bevevino joined Respiroics in 1988 and has served in a variety of positions with increasing responsibility in finance and accounting. Additionally, during his tenure at Respiroics, Mr. Bevevino has been responsible for certain operating, sales and marketing activities. He served as Controller from 1990-1994, Chief Financial Officer, Controller from 1994-1996 and was appointed Vice President, Chief Financial Officer in 1996.

"Thomas Ackerman and Dan Bevevino will bring valuable business experience and financial expertise to our Board of Directors," said Steven G. Anderson, Chairman and Chief Executive Officer. "We welcome them to our Board and we look forward to the contributions they will make to CryoLife."

CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's web site, <http://www.cryolife.com> .

Contact: Joseph T. Schepers  
Vice President, Corporate Communications  
(770) 419-3355

SOURCE CryoLife, Inc.